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1. Introduction 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that mostly attacks 
synovial joints, although other tissues and organs can be affected. The final effect is usually 
the destruction of articular cartilage and ankylosis of the joints, with a prevalence of the 
wrist and small joints of the hand. Diagnostic criteria have recently been revised (Aletaha et 
al., 2010; Neogi et al., 2010). The prevalence of RA is about 1% in the total population, being 
women more affected than men in a ratio of approximately 2-3:1 (Alamanos & Drosos, 
2005). 
RA is considered an autoimmune disorder, although the etiology and pathogenesis of the 
disease remain unclear. A complex set of factors are involved in the onset of the disease, 
including genetic and environmental. The strongest genetic association is with the genes 
encoding major histocompatibility complex (MHC, HLA in human) class II molecules 
(Gregersen et al., 1987; Stastny, 1978), although other genes have been associated with RA, 
including PTPN22, STAT4, TRAF1/C5, and others. 
Antibodies against the Fc fraction of IgG are found in the serum of about 80% of patients 
with RA. These autoantibodies are called rheumatoid factor (RF), and the consideration of 
RA as an autoimmune disease has largely been based on the presence of RF in the serum of 
patients. Nevertheless, the presence of RF is not exclusive of RA and that, together with the 
absence of definitive data demonstrating an arthritogenic effect of RF, suggest that these 
antibodies are produced as a consequence of the immune response rather than being the 
cause of it (Nemazee, 1985; Tarkowski et al., 1985). However, the adaptive immune response 
seems to play an important role in the disease as suggested by the strong association of RA 
with the presence of some HLA class II alleles. Autoantibodies against citrullinated proteins 
(ACPAs) have been described in the serum of about 50-70% of RA patients in comparison 
with about 2% of the healthy population (Avouac et al., 2006; Kroot et al., 2000; Nishimura 
et al., 2007; Schellekens et al., 2000; van Gaalen et al., 2004; Vincent et al., 2002). The presence 
of ACPAs is very stable during the course of the disease and is quite specific for RA. These 
antibodies can be detected several years before of symptomatic disease, making the presence 
of ACPAs a good clinical marker for RA. Patients containing ACPAs in the serum usually 
have a more severe disease. The presence of these antibodies correlates very well with the 
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presence of some of the HLA-DR alleles containing the “shared epitope” (see below). All of 
these data have led to the postulation that there actually are two different disorders 
(Klareskog et al., 2008). However, the cause of the specificity of the generation of ACPAs in 
RA and whether the antibodies are pathogenic or secondary to the joint inflammation 
remain unanswered. 
Many reports have been published in the last years describing some of the features of the 
antibodies that recognize citrullinated proteins and showing some of the proteins that are 
target of these autoantibodies. The generation of an effective B cell response requires the 
recognition by specific CD4+ T cells of peptides derived of the antigen in the context of MHC 
class II molecules. In this chapter some of the data indicating the importance of anti-
citrulline responses will be reviewed and concretely emphasize on reviewing the last reports 
dealing with MHC presentation and T cell responses to citrullinated peptides will be done. 
2. HLA and rheumatoid arthritis 
The strongest genetic association of RA susceptibility is with some specific HLA class II 
alleles. In Northern Europe, the strongest association is with the serotype HLA-DR4 
(Jaraquemada et al., 1986; Stastny, 1978). The association is with some allelic variants of 
HLA-DR4, including DRB1*0401, *0404, *0405 and *0408. However, other HLA-DR4 
subtypes do not confer predisposition to RA. In Southern Europe and other populations the 
susceptibility to RA is associated to alleles other than DR4. Thus, DRB1*0101, *0102, *1402 
and *1001 have been reported with predisposition to RA (Cutbush et al., 1993; de Juan et al., 
1994; Gonzalez-Escribano et al., 1999; Hameed et al., 1997; Lacki et al., 2000; Mody & 
Hammond, 1994; Poor et al., 2007; Salvarani et al., 1999; Sanchez et al., 1990; Yelamos et al., 
1993). A major feature shared by the alleles that confer susceptibility to RA is the presence of 
some residues at position 67 and 70-74 of the third hypervariable region of DRB1 (Table 1). 
Thus, the presence of specific residues in these positions (L…(Q/R)(K/R)RAA) led to the 
proposal of the “shared epitope” hypothesis (Gregersen et al., 1987), in which the molecular 
basis for the association of some alleles with RA was restricted to this critical region in the  
chain of HLA-DR molecules. The P4 residue of the peptide core directly interacts with some 
of the residues that are part of the shared epitope (SE). Other residues are exposed to 
outside the binding groove. Thus, the side chains of these amino acids could be involved in 
the pathogenesis of the disease by defining the peptide preference or directly interacting 
with the T cell receptor (TCR), influencing the T cell repertoire selection, and specific T cell 
activation. Alternatively, molecular mimicry of this HLA-DR region and proteins from 
pathogenic agents might contribute to the disease process. Other mechanisms have been 
proposed to explain the role that the SE plays in the disease, including direct triggering by 
the five-amino acid SE sequence leading to NO production (Ling et al., 2007), ability to bind 
to heat shock proteins (Auger et al., 1996), and the ability to present citrullinated peptides 
(Hill et al., 2003). A putative “protective epitope” has also been defined for the same region, 
with the sequence DERAA, corresponding to DRB1*0402, *1102, *1301, *1302, and *1304, and 
is associated with a less severe disease (van der Helm-van Mil et al., 2005).  
HLA genes show strong linkage disequilibrium, so they segregate as haplotypes with a low 
recombination rate, specially between HLA-DR and HLA-DQ. Different data indicate that 
some HLA-DQ alleles that segregate with given HLA-DR alleles play an important role in 
RA, although these data are not totally understood. The combination of the presence of the 
SE-containing HLA-DR alleles and specific HLA-DQ alleles opened the possibility that 
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peptides containing the SE can be presented to T cells in the context of specific HLA-DQ, 
shaping the T-cell repertoire (Salvat et al., 1994). 
 
 
Table 1. Residues in the shared epitope positions in HLA-DR molecules differentially 
associated to RA 
3. Citrullination 
Citrullination is a post-translational protein modification that consists in the deimination of 
the positive charged amino acid arginine, generating the neutral amino acid citrulline 
(Figure 1). The process requires high concentrations of Ca2+ and is produced in 
inflammatory environments (Baeten et al., 2001; Chavanas et al., 2004; Vossenaar et al., 
2003). Other mechanism that triggers arginine deimination is apoptosis (Baeten et al., 2001). 
Environmental insults such as smoking increases the expression of PAD2 and induces 
citrullination in the mouse (Makrygiannakis et al., 2008). 
The conversion of arginine to citrulline is carried out by a family of enzymes known as 
peptidyl arginine deiminases (PADs) (Vossenaar et al., 2003). Five members of this family of 
enzymes have been described in human (PAD1, PAD2, PAD3, PAD4 and PAD6). The 
members or this family are differentially expressed in many cell types (including neutrophils, 
monocytes, and macrophages) and tissues (Migliorini et al., 2005; Nijenhuis et al., 2004; van 
Venrooij & Pruijn, 2000; Vossenaar et al., 2003; Wysocka et al., 2006). Thus, PAD2 and PAD4 
are expressed in the synovium of patients with RA, but PAD1, PAD3 and PAD6 are not 
(Foulquier et al., 2007). At least some functional haplotypes of PAD4 are associated with RA 
(Suzuki et al., 2003). Interestingly, PAD4 is capable of self-citrullination, which can regulate its 
activity and control the citrullination of other proteins (Andrade et al., 2010). 
Citrullinated proteins have been detected in several inflamed tissues: arthritic joins 
(Vossenaar et al., 2004a), brain (Nicholas & Whitaker, 2002), muscle and lymphoid organs 
(Makrygiannakis et al., 2006) and lungs (Bongartz et al., 2007; Klareskog et al., 2006). In 
addition, some proteins from the epidermis and central nervous system are constitutively 
citrullinated (Kubilus et al., 1979; Nicholas et al., 2003). 
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The function of citrullination is not totally understood, although it is important in some 
physiological processes such as apoptosis (Asaga et al., 1998) and cell differentiation 
(Senshu et al., 1996). The loss of a positive charge can produce changes in some relevant 
protein features. Thus, electrostatic interactions are usually important in generating and 
maintaining protein structures. A citrullinated protein modifies some of the interactions that 
stabilize the native conformation, and decreases its isoelectric point, affecting the secondary 
and tertiary structure, which can result in a different protein folding that may modify the 
function of the protein (Gyorgy et al., 2006). Regarding the specific protein functions 
affected by citrullination it has been reported that arginine deimination influences protein–
protein interaction (Tarcsa et al., 1996), and can modulate signalling potency (Proost et al., 
2008). In addition, citrullinated proteins often change their sensitivity to degradation by 
proteolytic enzymes (Pritzker et al., 2000). 
 
 
Fig. 1. Conversion of arginine to citrulline. The protein posttranslational modification 
known as citrullination consists in a deimination of arginine to citrulline. The reaction is 
carried out by an enzyme of the family of peptidyl arginine deiminases (PAD), and requires 
high concentration of Ca2+. This reaction results in the loss of a positive charge in the 
protein. 
4. Citrulline and rheumatoid arthritis 
As mentioned above, the presence of citrullinated proteins is detected in the joints of 
patients with RA (Baeten et al., 2001), although it is not exclusive for rheumatoid synovial 
tissue (Vossenaar et al., 2004a). The specificity of citrullination has not been solved and 
several proteins have been found to be citrullinated in the synovium, including vimentin 
(Bang et al., 2007; Vossenaar et al., 2004b), fibrinogen (Masson-Bessiere et al., 2001), and 
collagen type II (Klareskog et al., 2008). The role of these modified proteins in the joints 
remains unknown, although some of these proteins are known targets of the autoimmune 
response. Thus, specific antibodies have been detected in RA patients that recognize 
citrullinated filaggrin (Nijenhuis et al., 2004; Schellekens et al., 1998; Sebbag et al., 1995; 
Simon et al., 1993), fibrinogen (Bang et al., 2007), vimentin (Burkhardt et al., 2005; Despres et 
al., 1994; Hayem et al., 1999; Hueber et al., 1999) and collagen type II (Burkhardt et al., 2005). 
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A relevant feature of ACPAs is that their presence is RA specific. Thus, in contrast with RF, 
patients with inflammatory diseases other than RA rarely carry ACPAs in serum. It still 
remains unclear why ACPAs are present in the serum of most RA patients but absent in the 
serum of other systemic autoinflammatory diseases. 
As with RF, the generation of ACPAs in the serum of RA patients can occur several years 
before the onset of the disease (Aho et al., 2000; Kurki et al., 1992; Nielen et al., 2004; 
Rantapaa-Dahlqvist et al., 2003). The detection of these ACPAs can be used as clinical tests 
to predict the clinical course of the disease (Kastbom et al., 2004; Ronnelid et al., 2005). There 
are some clinical and genetic differences between ACPA+ and ACPA- RA patients. 
Clinically, ACPA+ RA patients have a more severe disease course than patients without 
detectable ACPAs (Forslind et al., 2004; Kastbom et al., 2004; Kroot et al., 2000; Ronnelid et 
al., 2005). Genetically, the detection of ACPAs in the serum of RA patients correlates very 
well with the presence of HLA-DR alleles containing the SE, which does not happen with 
RF. Some reports have shown that the presence of HLA-DRB1 alleles containing the SE is 
directly related and restricted to the ACPA+ subset of RA (Huizinga et al., 2005; van der 
Helm-van Mil et al., 2006) and SE alleles influence both the magnitude and the specificity of 
this RA-specific antibody response (Verpoort et al., 2007). Other HLA-DRB1-independent 
genetic associations in the HLA region to ACPA positivity have been reported (Okada et al., 
2009). In contrast, ACPA- RA is not related with the SE-carrying HLA-DRB1 alleles and it 
has been associated with HLA-DRB1*03 (Irigoyen et al., 2005), an DRB1 allele that does not 
contain the SE. Taking together, it seems clear that ACPA+ and ACPA- RA do not present 
the same genetic background or clinical course and evidence strongly suggest that these are 
two different RA subsets, so they should be considered as different entities when treated.  
Since ACPAs are developed before the onset of the disease and their presence predicts a 
more severe clinical course, this seems to indicate that the immune response against 
citrullinated proteins contribute to the pathogenesis of this form of RA.  
5. Citrullinated peptides and HLA 
The SE contains residues 70-74 of the DR chain, and is located in one -helix of the binding 
groove. These residues are located in a position such that some of them can interact with the 
peptide bound to the HLA-DR molecule. Concretely, the crystal structures of HLA-DR1 and 
HLA-DR4 with different peptides have shown that the residues Lys71 in DRB1*0401 and 
Arg71 in DRB1*0101 directly interact with the amino acid located in position 4 (P4) of the 
peptide core bound to the binding groove of HLA-DR molecules (Dessen et al., 1997; 
Rosloniec et al., 2006). The binding motifs of the peptides associated to HLA-DR1 and HLA-
DR4 were described years ago. More recently, our group reported an exhaustive analysis of 
the peptide pool associated to HLA-DR10 by mass spectrometry and identified the anchor 
motif of the peptide repertoire bound to this RA-associated allele (Alvarez et al., 2008). This 
motif was consistent with a more recent report by Kwok´s group using an approach based 
on binding assays (James et al., 2010). An important structural information extracted from 
these data is that HLA-DR molecules containing the SE do not bind peptides with basic 
residues in P4 position. This is due to the presence of basic residues at position 71 of the 
HLA-DR  chain (table 1). 
Conversion of the basic amino acid arginine to the neutral citrulline produces the loss of a 
net positive charge on the protein or peptide that suffer this post-translational modification. 
Thus, citrulline is a neutral, polar, large amino acid with structural features similar to 
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glutamine. Interestingly, peptides with arginine in P4 are poorly tolerated for the HLA-DR 
molecules that comprise the SE alleles (Fremont et al., 1996; Friede et al., 1996), while 
peptides with glutamine in P4 of the binding core have been described for DRB1*0101, 
DRB1*0401 and DRB1*1001 (Alvarez et al., 2008; Dengjel et al., 2005; Muntasell et al., 2004; 
Stern et al., 1994; Verreck et al., 1996). Basic residues, such as arginine or lysine, in P4 
position of the peptide core produce electrostatic repulsion with the basic residues in 
position 71 of the  chain in the HLA-DR molecules that contain the SE. However, glutamine 
can accommodate well in the pocket and can be stabilized by hydrogen bonds with Arg71 or 
Lys71 in the HLA-DR  chain. Thus, positively charged amino acids (e.g., arginine) in P4 
inhibit peptide binding to RA-related HLA-DR molecules containing the SE, whereas 
peptides with uncharged polarity (e.g., glutamine) are bound to these molecules with high 
affinity (Hammer et al., 1994; Hammer et al., 1995). Peptides with citrullin in P4 would 
interact favourably at the P4 anchoring pocket of SE-containing HLA-DR molecules. This 
was confirmed both for DRB1*0101, DRB1*0401 (Hill et al., 2003) and DRB1*1001 (James et 
al., 2010). Concretely, modified peptides derived from joint associated proteins were able to 
bind to RA-associated MHC molecules: the peptide spanning residues 65-77 from vimentin, 
vimentin (65-77) to DRB1*0101 and DRB1*0401 (Hill et al., 2003), and peptides vimentin (58-
72), Fib A (737-751), Fib B (68-82) and cartilage intermediate layer protein CILP (982-996) to 
DRB1*1001 (James et al., 2010). These data open the possibility that in the inflamed joint, 
some arginines may be deiminated by activated PAD2 or PAD4 and, after protein 
catabolism, citrulline-containing peptides would be bound to SE HLA-DR molecules. 
The peptide repertoires associated to many MHC molecules have been described, both for 
MHC class I and for MHC class II. However, up to now, no peptide with citrulline in P4 has 
been reported to be a natural ligand of any HLA-DR molecule. Some reasons make the 
identification of citrullinated peptides from the peptide repertoire bound to HLA-DR 
molecules very difficult. First, the conditions to obtain high level of protein citrullination are 
not totally controlled, although some protocols have been reported, as increasing intracellular 
calcium by the addition of ionomicine to the cell culture (Vossenaar et al., 2004c). Second and 
more important, after deimination induction, most of the peptides will remain containing 
arginine instead of citrulline, and probably, the amount of citrullinated peptides in the peptide 
pool will be low. Mass spectrometry analysis give information of the most abundant peptides 
in the MHC-associated peptide pools making complicated to find a low-abundance 
citrullinated peptide. An approach that could be used to solve these problems would be to 
enrich citrullinated peptides in the sample. Antibodies specific for citrullinated peptides can 
not be used because they can recognize some peptides but not others. A technique for the 
specific enrichment of citrulline-containing peptides has been described, based on the 
immobilization of a glyoxal derivative that reacts exclusively with the ureido group of the 
citrulline residue al low pH (Tutturen et al., 2010). The ureido group can be chemically 
modified by diacetyl monoxime and antipyrine (Senshu et al., 1992). The chemically modified 
citrulline can be detected, using a specific antibody, by Western blotting and 
immunohistochemistry (Makrygiannakis et al., 2008). Peptides or proteins containing the 
modified citrulline can also be detected by mass spectrometry (Stensland et al., 2009). 
6. T cell responses to HLA-restricted citrullinated peptides 
The induction of a typical humoral response that results in a production of classes of 
antibodies others than IgM requires the help of CD4 T cells. T cells recognize complexes 
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formed by MHC molecules and peptides derived from antigenic proteins. In the case of 
ACPAs, the targets of the immune response are modified self proteins, as vimentin, fillagrin, 
fibrinogen and collagen type II. CD4 T cells that help in the generation of an anti-
citrullinated proteins B cell response do not necessarily recognize citrullinated peptides. 
However, a role of T cell responses in RA is well known, which makes the identification of T 
cell responses against citrullinated peptides presented in the context of RA-related HLA-DR 
of great interest. These peptides could be citrullinated outside the binding core, in the core 
positions other than P4, or in P4, as discussed above. 
In the last years, T cell responses to citrulline-containing peptides have been studied. First, 
using DR4-IE transgenic mice (expressing the chimeric molecule DR4-IE, that contains the 
DR4 binding groove and part of the murine class II molecule), Hill and collaborators 
demonstrated that deimination of arginine to citrulline significantly increased the peptide-
MHC affinity when arginine was in P4 position. In addition, activated CD4+ T cells were 
detected in these transgenic mice against a peptide spanning residues 65 to 77 of vimentin, 
vimentin (65-77), which had a citrulline in position 70 instead of the arginine of the 
unmodified protein. These results revealed that HLA-DRB1 alleles with the SE could initiate 
an specific autoimmune response to citrullinated self-antigens in DR4-transgenic mice (Hill 
et al., 2003). In this animal model, citrullinated fibrinogen induced arthritis. The disease 
induced in these mice was characterized by synovial hyperplasia followed by ankylosis, but 
lacked a large leukocyte infiltrate. Specific humoral and cellular responses to citrullinated 
components were observed, which were absent in wild-type mice immunized with 
citrullinated or unmodified fibrinogen and in transgenic mice immunized with unmodified 
fibrinogen (Hill et al., 2008). HLA-DRB1*0401–restricted T cell reactivity to fibrinogen (371-
383) was clearly seen in transgenic mice after immunization with either citrullinated 
fibrinogen or unmodified fibrinogen, whereas no specific response to this peptide was 
detected in wild-type mice. Ten peptides derived from ,  or  chains of human fibrinogen 
containing an aliphatic or aromatic residue in P1 position of the binding core and arginine 
or citrulline at P4 were tested to generate T cell responses. Only one citrullinated peptide, 
FibαR84Cit, induced a consistent T cell response, whereas no response was seen against the 
corresponding arginine-containing peptide Fibα79-91. Therefore, these data confirm that a 
citrullinated protein can be arthritogenic when RA-associated alleles are expressed, and 
specific T cell responses to citrullinated peptides are part of the immune response. 
Citrullinated peptides-specific T cell activation plays an important role in the development 
and progression of arthritis in this animal model. Thus, when given prior to disease onset, 
treatment with CTLA-4Ig, an agent that blocks T cell costimulation, prevented T cell 
activation induced by citrullinated human fibrinogen. This effect was not seen with non-
specific IgG1 (Yue et al.). 
Other approach using the mouse model detected that a response against citrullinated 
peptides could be generated even when the antigen was administrated in unmodified form. 
Concretely, HEL was used as a model antigen, and T cells specifically reactive to 
citrullinated epitopes were detected among the responding repertoire to immunization with 
an unmodified HEL protein. In addition, antigen presenting cells (APCs), including 
dendritic cells and peritoneal macrophages, were able to present citrullinated peptides when 
provided an intact, unmodified HEL ex vivo (Ireland et al., 2006). Therefore, APCs were 
capable to capture and process the antigen, to deiminate some specific arginine residues and 
to present some citrullin-containing peptides to T cells in a correct way to induce an specific 
response against citrullinated peptides. 
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More than 90% of patients positive for citrullinated vimentin-specific ACPAs carry SE-
containing HLA-DRB1 alleles. In a DR4-transgenic mouse model, animals were immunized 
with 33 citrulline-containing peptides (all possible citrullinated peptides of human 
vimentin) and tested for T cell reactivity. T cell responses were generated against some of 
these peptides restricted by HLA-DRB1*0401 (vimentin (26-44) and vimentin (415-433). 
Antigen presenting cells were able to generate these peptides from entire vimentin. In 
addition, T cell reactivity against these citrullinated peptides derived from vimentin were 
observed when PBMCs from ACPAs-positive, HLA-DR4-positive patients with RA were 
used (Feitsma et al.). These data strongly suggest the presence of HLA-DRB1*0401-restricted 
T cell responses against citrullinated vimentin-derived peptides in RA patients. The data do 
not exclude T cell responses against non-citrullinated peptides restricted by this or other 
HLA-DRB1 alleles, that also could facilitate a humoral response against citrullinated 
epitopes. 
The generation of T cell responses against citrullinated peptides has also been confirmed for 
other autoantigens. Thus, a proliferative response was observed in more than 60% RA 
patients after stimulation with citrullinated aggrecan-derived peptide, aggrecan (84-103) 
(von Delwig et al., 2010). This response was absent in PBMCs from healthy controls, and 
there was no response to the unmodified aggrecan analog peptide, indicating that citrulline 
residue is required for T cell recognition. In addition, cytokine production was analyzed by 
ELISA and intracellular cytokine analysis. High levels of the proinflammatory cytokine 
interleukin-17 (IL-17) was produced by PBMCs from RA patients in response to stimulation 
with citrullinated aggrecan. This IL-17 production was absent when PBMCs from RA 
patients and healthy controls were stimulated with the unmodified aggrecan-derived 
peptide. Therefore, citrullinated aggrecan-specific T cells may play a role in the 
pathogenesis of RA and in the inflammatory process.  
Most of the T cell responses to citrullinated peptides have been generated in models that 
express HLA-DRB1*0401. In addition, responses against citrullinated peptides restricted by 
the RA-associated, SE-containing HLA-DRB1*1001 molecule have been obtained (James et 
al., 2010). Authors demonstrated that HLA-DRB1*1001 can accommodate citrulline in three 
anchor positions, and three of the modified peptides that were evaluated developed specific 
CD4+ T cell responses. These peptides derived from fibrinogen , fibrinogen  and cartilage 
intermediate-layer protein, and these data suggest a role for these three proteins as relevant 
antigens in RA in HLA-DRB1*1001+ patients. In addition, T cell clones specific for these 
sequences proliferated only in response to citrullinated peptides. One more time, these data 
suggest that deimination of arginine can have as a consequence the generation of new HLA-
DR ligands that can be recognized by T cells as neoepitopes, and may play an important role 
in the initiation or progression of RA. As described recently, T cell responses to other post-
translational modifications may play a similar role in generating inflammatory responses. 
One of this could be carbamylation of lysine to homocitrulline. Thus, mice were immunized 
with carbamylated peptides, which induced chemotaxis, and T and B cell responses. Mice 
immunized with carbamylated peptides developed erosive arthritis when citrullinated 
peptides were injected intra-articularly. In addition, T and B cells induced arthritis after 
adoptive transfer into normal recipients (Mydel et al., 2010). Therefore, the T cell response to 
homocitrulline-derived peptides, as well as the subsequent production of anti-
homocitrulline Abs, was critical for the induction of autoimmune responses against 
citrulline-derived peptides which may provide a novel mechanism for the pathogenesis of 
arthritis. 
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Constitutive protein citrullination occurs in some tissues in absence of inflammation, which 
imply the existence of tolerance against these modified proteins. The thymus is the organ 
where the immunocompetent T cell repertoire is generated. During selection processes to 
generate central T cell tolerance, about 95-97% of the thymocytes die by apoptosis, which is 
an inductor of citrullination. Thus, PAD activity and arginine deimination may be active in 
this organ. Citrullinated peptides that bind to HLA-DR molecules in the thymus should not 
be able to induce an immune response in periphery. Differences in the machinery of antigen 
processing have been reported between thymic cells and other presenting cells. Thus, the 
identification and analysis of HLA-DR-associated citrullinated peptides in the thymus could 
reveal which peptides can generate central tolerance. 
7. Conclusions 
The finding that the sera of most RA patients contain antibodies specifc for citrullinated 
proteins opened the possibility of a new mechanism in the etiology of the disease. These 
antibodies are specific for RA, can be detected years before the development of the disease, 
and correlate with the presence of SE-containing alleles. In the last years, relevant advances 
on the identification of the citrullination process in the inflamed joints by PADs´activity, the 
presentation by RA-associated HLA-DR molecules that contain the SE, and T cell responses 
against citrullinated proteins have been made. Nevertheless, it remains to be defined which 
citrullinated peptides are really involved in the development of the disease in humans and if 
any of them can efficiently be presented in the context of various SE-containing HLA-DR 
molecules. 
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